{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:38:18Z","timestamp":1793914698292,"version":"4.8.0"},"reference-count":54,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Child Neurology Open"],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a genetic condition characterized by progressive motoneuron loss. Infants affected by SMA type 1 do not gain developmental milestones and acutely decline, requiring ventilatory support. Several scales are used to assess motor disability and its progression in SMA. Recently, 3 disease-modifying therapies have been approved for SMA patients: nusinersen, an intrathecal antisense oligonucleotide enhancing SMN protein production by the SMN2 gene, risdiplam, also influencing the SMN2 gene to stimulate SMN production but administered orally, and onasemnogene abeparvovec-xioi, an SMN1 gene replacement therapy. Thus, the functional scales should now be applicable for patients improving their motor function over time to assess treatment efficacy. In this paper, we compare different functional scales used in SMA patients. Their usefulness in different SMA types, age groups, and feasibility in daily clinical practice is described below. Some changes in motor function assessments in SMA are also suggested.<\/jats:p>","DOI":"10.1177\/2329048x211008725","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T03:41:10Z","timestamp":1619494870000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":54,"title":["Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-8083","authenticated-orcid":false,"given":"Katarzyna","family":"Pierzchlewicz","sequence":"first","affiliation":[{"name":"Department of Neurology and Epileptology, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"K\u0119pa","sequence":"additional","affiliation":[{"name":"Department of Neurology and Epileptology, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Podogrodzki","sequence":"additional","affiliation":[{"name":"Department of Neurology and Epileptology, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[{"name":"Department of Neurology and Epileptology, Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"bibr1-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"bibr2-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.8.4.481"},{"key":"bibr3-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/96.3.463"},{"key":"bibr4-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190428"},{"key":"bibr5-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"bibr6-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64076-5.00038-7"},{"key":"bibr7-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2008.10.004"},{"key":"bibr8-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23937"},{"key":"bibr9-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(91)90051-S"},{"key":"bibr10-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2015.12.007"},{"key":"bibr11-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.10.002"},{"key":"bibr12-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(91)90052-T"},{"key":"bibr13-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)00075-K"},{"key":"bibr14-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"bibr15-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1038\/344540a0"},{"key":"bibr16-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1126\/science.7910982"},{"key":"bibr17-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"bibr18-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.006"},{"key":"bibr19-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1111\/joa.12083"},{"key":"bibr20-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1177\/1756285618754501"},{"key":"bibr21-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002"},{"key":"bibr22-2329048X211008725","unstructured":"Walsh S. Published 2016. Accessed March 09, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-spinal-muscular-atrophy"},{"key":"bibr23-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0545-1"},{"key":"bibr24-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1364159"},{"key":"bibr25-2329048X211008725","unstructured":"Biogen Idec Ltd. Spinraza 12 mg solution for injection. Summary of Product Characteristics. 2020. Updated January 31, 2021."},{"key":"bibr26-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002"},{"key":"bibr27-2329048X211008725","unstructured":"O\u2019Keefe L. Published 2020. Accessed March 09, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy"},{"key":"bibr28-2329048X211008725","unstructured":"An open label study of LMI070 (branaplam) in type 1 spinal muscular atrophy (SMA). Publihsed 2014. Accessed March 09, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268552"},{"key":"bibr29-2329048X211008725","unstructured":"Caccomo S. Published 2019. Accessed March 09, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease"},{"key":"bibr30-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"bibr31-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.02.006"},{"key":"bibr32-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.03.015"},{"key":"bibr33-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12876"},{"key":"bibr34-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.11.014"},{"key":"bibr35-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1097\/PEP.0b013e3182351f04"},{"key":"bibr36-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1097\/PEP.0b013e3182352896"},{"key":"bibr37-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25705"},{"key":"bibr38-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.05.009"},{"key":"bibr39-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.01.003"},{"key":"bibr40-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.08.001"},{"key":"bibr41-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.03.005"},{"key":"bibr42-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1177\/0883073811420294"},{"key":"bibr43-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(03)00060-6"},{"key":"bibr44-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172346"},{"key":"bibr45-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23937"},{"key":"bibr46-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1177\/15648265040251S106"},{"key":"bibr47-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25430"},{"key":"bibr48-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25120"},{"key":"bibr49-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-13-49"},{"key":"bibr50-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10166"},{"key":"bibr51-2329048X211008725","unstructured":"Hospital Nationwide Children\u2019s. Accessed March 09, 2021. https:\/\/www.nationwidechildrens.org\/research\/areas-of-research\/center-for-gene-therapy\/lowes-lab\/neuromuscular-gross-motor-outcome-gro"},{"key":"bibr52-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.7.937"},{"issue":"50","key":"bibr53-2329048X211008725","first-page":"2632","author":"Ciesla N","year":"2011","journal-title":"J Vis Exp"},{"key":"bibr54-2329048X211008725","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"}],"container-title":["Child Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2329048X211008725","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2329048X211008725","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2329048X211008725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:58:05Z","timestamp":1777391885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2329048X211008725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":54,"alternative-id":["10.1177\/2329048X211008725"],"URL":"https:\/\/doi.org\/10.1177\/2329048x211008725","relation":{},"ISSN":["2329-048X","2329-048X"],"issn-type":[{"value":"2329-048X","type":"print"},{"value":"2329-048X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"article-number":"2329048X211008725"}}